The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.
 
Martin David Forster
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Merck; Merck Sharp & Dohme; Pfizer; Roche
 
Ruheena Mendes
No Relationships to Disclose
 
Kevin J. Harrington
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Merck
Speakers' Bureau - Amgen; Merck
Research Funding - AstraZeneca
 
Teresa Guerrero Urbano
No Relationships to Disclose
 
Helen Baines
No Relationships to Disclose
 
Victoria J Spanswick
No Relationships to Disclose
 
Leah Ensell
No Relationships to Disclose
 
John A. Hartley
Employment - MedImmune
 
Sola Adeleke
No Relationships to Disclose
 
Paul Gougis
No Relationships to Disclose
 
David Leader
No Relationships to Disclose
 
Cathy McDowell
No Relationships to Disclose
 
Andre Lopes
No Relationships to Disclose
 
Jonathan Teague
No Relationships to Disclose
 
Sharon Forsyth
No Relationships to Disclose
 
Sandy Beare
No Relationships to Disclose